• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus

    1/15/26 7:15:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $IDXX alert in real time by email

    A fully connected imaging ecosystem – centralized access, integrated workflows, and AI-powered imaging to accelerate diagnosis and elevate care

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the launch of the ImageVue™ DR50 Plus Digital Imaging System, its most advanced diagnostic imaging solution for veterinary practices. Designed to set a new standard, the system combines high definition, AI-powered imaging at the lowest dose of radiation – reducing exposure by up to 25% compared to IDEXX's current best-in-class ImageVue™ DR50 system1 and up to 60% compared to other veterinary imaging solutions2. Coupled with IDEXX's connected end-to-end imaging workflows, this breakthrough helps veterinary teams make faster, more confident decisions, while setting a new benchmark for radiation safety.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115640691/en/

    Image quality comparison between ImageVue DR50 and ImageVue DR50 Plus

    Image quality comparison between ImageVue DR50 and ImageVue DR50 Plus

    Radiography is a standard diagnostic technique in nearly every U.S. veterinary clinic3, and an estimated 75% of technicians are women of childbearing age4, underscoring the importance of minimizing exposure to protect team health and safety. The ImageVue DR50 Plus combines advanced image optimization, automated protocols, and irradiated side sampling technologies to adjust for positioning and technique variability, helping reduce retakes. Its unique design captures x-ray signals more efficiently, producing sharper images with less radiation. In addition to the 14" x 17" panel, a new 17" x 17" panel option expands coverage across a wider range of patients, and seamless integration with IDEXX software and telemedicine solutions ensures a smooth end-to-end workflow.

    "The ImageVue DR50 Plus system marks a new chapter in diagnostic imaging, delivering exceptional image quality and advancing radiation safety," said Jay Mazelsky, President and Chief Executive Officer of IDEXX. "As the lowest-dose system to date, it expands clinical insight, reduces retakes, and streamlines the imaging workflow from capture to consult through seamless integration with our software and telemedicine solutions."

    The ImageVue DR50 Plus system enables a connected diagnostic imaging workflow for veterinary professionals:

    • IDEXX Web PACS™ Software provides centralized image access, viewing, sharing, and storage, fully embedded into efficient veterinary practice workflows. Its AI-powered viewer automates hanging protocols and vertebral heart scores, reducing manual steps and saving time on diagnosis.
    • IDEXX Telemedicine Consultants offer 24/7 expert insights for routine and complex cases, with 160+ board-certified specialists worldwide across radiology, cardiology, and other disciplines. Customers can now submit and review IDEXX Telemedicine cases directly through Web PACS. The new connection reduces the number of clicks required to submit a case by more than 45%, allowing more time for patient care5.
    • ezyVet™ Practice Management Software enables veterinarians to retrieve images from IDEXX Web PACS, submit cases to IDEXX Telemedicine Consultants, and automatically receive results in the corresponding patient record.

    "As a veterinarian, providing timely, accurate diagnoses while ensuring patient and staff safety is my top priority," said Dr. Jean C. K. Pitcairn, DVM, CVC, CCRP, CVCHM, CHPCP Integrative Oncology, Medical Director of Chase Farm Veterinary Hospital.* "The ImageVue DR50 Plus system consistently delivers sharp, detailed images with a low dose of radiation, allowing us to make confident decisions and focus on quality care. The images are high quality, and I can show pet owners exactly what I see, building trust through transparency."

    The ImageVue DR50 Plus Digital Imaging System is currently available to veterinary clinics in the United States and Canada. For more information, visit the IDEXX ImageVue DR50 Plus web page.

    References

    1. Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: Dose comparison of ImageVue DR50 and ImageVue DR50 Plus digital imaging systems.
    2. Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: Based upon comparison of IDEXX systems to comparable digital imaging systems currently available in the veterinary market.
    3. Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA.
    4. Aggregated data on Veterinary Technologists and Technicians from the 2023 US Census by Data USA. Accessed November 5, 2025. https://datausa.io/profile/soc/veterinary-technologists-and-technicians
    5. Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: Based on IDEXX Web PACS Embedded send compared to non-embedded Telemedicine case submission.

    *From time to time, Dr. Pitcairn has received compensation for consulting services she has provided to IDEXX.

    About IDEXX

    IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500TM Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com.

    Note Regarding Forward-Looking Statements

    This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," "project," and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at sec.gov and via IDEXX's website at idexx.com).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260115640691/en/

    Media Relations

    [email protected]

    Investor Relations

    [email protected]

    Get the next $IDXX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IDXX

    DatePrice TargetRatingAnalyst
    12/9/2025$850.00Overweight
    Barclays
    10/31/2025$700.00Hold → Buy
    Stifel
    10/1/2025$720.00Neutral
    UBS
    8/5/2025$545.00 → $785.00Buy
    BTIG Research
    7/1/2025$625.00Buy
    Jefferies
    12/2/2024$500.00Outperform
    Leerink Partners
    7/25/2024$580.00Buy
    BTIG Research
    1/30/2024$525.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $IDXX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus

    A fully connected imaging ecosystem – centralized access, integrated workflows, and AI-powered imaging to accelerate diagnosis and elevate care IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the launch of the ImageVue™ DR50 Plus Digital Imaging System, its most advanced diagnostic imaging solution for veterinary practices. Designed to set a new standard, the system combines high definition, AI-powered imaging at the lowest dose of radiation – reducing exposure by up to 25% compared to IDEXX's current best-in-class ImageVue™ DR50 system1 and up to 60% compared to other veterinary imaging solutions2. Coupled with IDEXX's connected end-t

    1/15/26 7:15:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs

    Cancer Dx expansion and inVue Dx FNA combine preventive screening and rapid, in-clinic diagnosis, enabling veterinarians and pet owners to act with confidence IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced two major advancements in veterinary cancer diagnostics: the expansion of its IDEXX Cancer Dx™ Panel to include canine mast cell tumor detection, starting mid-year 2026 in North America, and the rollout of FNA cytology on the IDEXX inVue Dx™ Cellular Analyzer, as of late Q4 2025. Together, these innovations will deliver earlier insights and rapid, in-clinic answers, helping veterinary teams guide timely treatment decisions. With mas

    1/15/26 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Announces CEO Succession

    Michael Erickson, PhD, to Succeed Jay Mazelsky as President and CEO; Mazelsky to Serve as Executive Chair of the Board of Directors IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the promotion of Michael (Mike) Erickson, PhD, to President and Chief Executive Officer, effective May 12, 2026, at which time Jonathan (Jay) Mazelsky, President and CEO, will transition to the role of Executive Chair of IDEXX's Board of Directors (the "Board"). Mr. Mazelsky has announced his intention to retire from the Company immediately following the Company's annual meeting of shareholders in May 2027, and will work closely with Dr. Erickson throughout t

    1/13/26 8:30:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    SEC Filings

    View All

    IDEXX Laboratories Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

    1/13/26 8:33:54 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

    11/13/25 4:07:10 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by IDEXX Laboratories Inc.

    10-Q - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

    11/3/25 4:13:42 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Peacock Karen

    4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

    12/3/25 5:01:16 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Executive Vice President Hunt Nimrata sold $6,629,014 worth of shares (9,425 units at $703.34) and exercised 12,530 shares at a strike of $382.28, increasing direct ownership by 17% to 21,149 units (SEC Form 4)

    4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

    11/10/25 5:01:13 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Hooley Joseph L was granted 39 shares (SEC Form 4)

    4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

    11/3/25 5:00:14 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on IDEXX Labs with a new price target

    Barclays initiated coverage of IDEXX Labs with a rating of Overweight and set a new price target of $850.00

    12/9/25 8:50:15 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Labs upgraded by Stifel with a new price target

    Stifel upgraded IDEXX Labs from Hold to Buy and set a new price target of $700.00

    10/31/25 8:14:50 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    UBS initiated coverage on IDEXX Labs with a new price target

    UBS initiated coverage of IDEXX Labs with a rating of Neutral and set a new price target of $720.00

    10/1/25 8:53:24 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Leadership Updates

    Live Leadership Updates

    View All

    Bonsai Health Names ModMed Veteran Rick Trefzger Chief Revenue Officer

    Former Modernizing Medicine sales leader joins Bonsai to accelerate growth of its agentic AI platform for healthcare practices. Bonsai Health, the agentic AI platform automating complex healthcare workflows, today announced that Rick Trefzger has joined the company as Chief Revenue Officer (CRO). Trefzger joins Bonsai after nearly 11 years at Modernizing Medicine (ModMed), where he was an early employee and served as vice president of sales, helping scale the company into the leading specialty-specific EHR platform serving dermatology, ophthalmology, orthopedics, gastroenterology, and other core specialties. During his tenure, ModMed grew into one of the most widely adopted specialty te

    10/16/25 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Elects Karen Peacock to Board of Directors

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company's Board of Directors, effective October 6, 2025. "We are extremely pleased to welcome Karen to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Karen is a highly accomplished executive with deep B2B, SaaS software and AI experience gained through building and running software and technology companies at various lifecycle stages. We are confident that her extensive professional experience and skills will complement those of our other Board members and contribute to our Board's overal

    10/7/25 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Jay is an accomplished executive who brings extensive strategic thinking and financial leadership experience, along with investor perspective, from his tenure leading State Street during a period of global growth and technological transformation. Given his substantial public company board and corporate governance experience and his unique backgro

    7/10/25 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Financials

    Live finance-specific insights

    View All

    IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial results for Monday, February 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telep

    1/9/26 1:30:00 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Announces Third Quarter Results

    Achieves third quarter revenue growth of 13% as reported and 12% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. Strong organic revenue growth was supported by IDEXX execution and commercial performance, reflecting benefits from IDEXX's innovation, including over 1,700 IDEXX inVue Dx™ placements. Delivers EPS of $3.40, an increase of 21% as reported and 15% on a comparable basis, including operating margin expansion of 100 basis points as reported and 120 basis points on a comparable basis. Increases 2025 revenue guidance to $4,270 million - $4,300 million, an increase of $43 million or ~1% at midpoint, reflecting stronger CAG Diagnosti

    11/3/25 6:30:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories to Release 2025 Third Quarter Financial Results

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 third quarter financial results for Monday, November 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen

    10/8/25 2:00:00 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.

    SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

    11/12/24 3:48:28 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.

    SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

    11/4/24 11:47:05 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by IDEXX Laboratories Inc. (Amendment)

    SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

    2/13/24 5:06:19 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care